The Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing (OAR) is a research registry (database). The purpose of the registry is to observe short- and long-term clinical outcomes in heart transplant recipients who receive regular AlloMap testing as part of allograft rejection surveillance.
This trial will study a new biomarker, dd-cfDNA, which scientists propose is a marker for cellular injury caused by rejection. Participation in the AlloMap registry (listed above) is a prerequisite to participation in this study.
Get Care Now
Get care for low-level urgent conditions through a video chat with a provider, 24/7, on your computer or mobile device.Learn More.
View wait times and save your place in line at an Intermountain InstaCare location near you.
If this is an emergency please go to the nearest emergency room or call 911.
Copyright ©2023, Intermountain Healthcare, All rights reserved.